John Fallon, Ph.D.

Fallon’s research focuses on quantitative targeted proteomics (QTAP) using nano- and microLC-MS/MS. The methods employ proteolytic digestion followed by representative peptide detection. Proteins quantified include drug metabolizing enzymes, such as CYP450s, and transporters, often in complex biological matrices such as liver, kidney, intestine and lung. The methods have applicability in characterizing drug response, including adverse drug reactions, as well as in understanding disease progression and treatment. The techniques are being expanded to the quantification of proteins associated with various cancers and the immune system. As a researcher in the Center for Nanotechnology in Drug Delivery Fallon uses QTAP to help bridge the knowledge gap between the use of modern drug delivery materials and their effects on protein expression in biological systems.

Education, Certification and Licensure

• 1991: B.Pharm. (Second Class Honours, First Division) in Pharmacy from University of Bradford
• 1999: Ph.D. in Drug Metabolism and Bioanalysis from King’s College London

ORCID iD: 0000-0003-1848-0121